AbbVie Inc. $ABBV Shares Sold by Souders Financial Advisors

Souders Financial Advisors reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 30.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,181 shares of the company’s stock after selling 3,509 shares during the quarter. Souders Financial Advisors’ holdings in AbbVie were worth $1,518,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Trek Financial LLC boosted its holdings in shares of AbbVie by 13.2% in the first quarter. Trek Financial LLC now owns 8,203 shares of the company’s stock valued at $1,719,000 after acquiring an additional 955 shares in the last quarter. Silverlake Wealth Management LLC boosted its holdings in shares of AbbVie by 9.0% in the first quarter. Silverlake Wealth Management LLC now owns 9,713 shares of the company’s stock valued at $2,035,000 after acquiring an additional 801 shares in the last quarter. Finally, New Insight Wealth Advisors boosted its holdings in shares of AbbVie by 2.1% in the first quarter. New Insight Wealth Advisors now owns 4,144 shares of the company’s stock valued at $868,000 after acquiring an additional 84 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.25% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Guggenheim boosted their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Wall Street Zen raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Piper Sandler reissued an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a report on Wednesday. Finally, HSBC set a $225.00 price objective on shares of AbbVie in a report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $238.05.

AbbVie Stock Performance

Shares of ABBV opened at $216.96 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a market capitalization of $383.27 billion, a price-to-earnings ratio of 103.31, a PEG ratio of 1.42 and a beta of 0.50. The company’s 50 day simple moving average is $222.84 and its 200 day simple moving average is $201.84. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the prior year, the firm posted $3.00 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.